News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
291,376 Results
Type
Article (9502)
Company Profile (29)
Press Release (281845)
Multimedia
Podcasts (41)
Webinars (5)
Section
Business (96592)
Career Advice (1075)
Deals (17464)
Drug Delivery (30)
Drug Development (32796)
Employer Resources (41)
FDA (5733)
Job Trends (5543)
News (151575)
Policy (10228)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (573)
Accelerated approval (13)
Adcomms (12)
Allergies (50)
Alliances (17504)
ALS (65)
Alzheimer's disease (521)
Antibody-drug conjugate (ADC) (165)
Approvals (5906)
Artificial intelligence (160)
Autoimmune disease (58)
Automation (8)
Bankruptcy (122)
Best Places to Work (4360)
BIOSECURE Act (2)
Biosimilars (65)
Biotechnology (26)
Bladder cancer (81)
Brain cancer (26)
Breast cancer (308)
Cancer (2073)
Cardiovascular disease (150)
Career advice (863)
Career pathing (13)
CAR-T (128)
CDC (8)
Cell therapy (336)
Cervical cancer (12)
Clinical research (29088)
Collaboration (576)
Company closure (2)
Compensation (416)
Complete response letters (24)
COVID-19 (786)
CRISPR (32)
C-suite (567)
Cystic fibrosis (47)
Data (2733)
Denatured (2)
Depression (54)
Diabetes (179)
Diagnostics (2728)
Digital health (10)
Diversity (1)
Diversity, equity & inclusion (15)
Drug discovery (72)
Drug pricing (43)
Drug shortages (8)
Duchenne muscular dystrophy (92)
Earnings (49399)
Editorial (16)
Employer branding (7)
Employer resources (43)
Events (47164)
Executive appointments (701)
FDA (7075)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (13)
Funding (565)
Gene editing (68)
Generative AI (8)
Gene therapy (238)
GLP-1 (367)
Government (958)
Grass and pollen (1)
Guidances (274)
Healthcare (6821)
HIV (21)
Huntington's disease (20)
IgA nephropathy (26)
Immunology and inflammation (103)
Immuno-oncology (23)
Indications (40)
Infectious disease (865)
Inflammatory bowel disease (68)
Inflation Reduction Act (6)
Influenza (32)
Intellectual property (61)
Interviews (184)
IPO (9125)
IRA (10)
Job creations (1319)
Job search strategy (753)
JPM (25)
Kidney cancer (11)
Labor market (35)
Layoffs (206)
Leadership (19)
Legal (2597)
Liver cancer (43)
Longevity (5)
Lung cancer (285)
Lymphoma (199)
Machine learning (11)
Management (14)
Manufacturing (233)
MASH (84)
Medical device (5412)
Medtech (5428)
Mergers & acquisitions (8907)
Metabolic disorders (490)
Multiple sclerosis (53)
NASH (16)
Neurodegenerative disease (111)
Neuropsychiatric disorders (26)
Neuroscience (1005)
NextGen: Class of 2026 (2256)
Non-profit (1255)
Now hiring (11)
Obesity (219)
Opinion (108)
Ovarian cancer (61)
Pain (56)
Pancreatic cancer (92)
Parkinson's disease (96)
Partnered (10)
Patents (96)
Patient recruitment (170)
Peanut (20)
People (30589)
Pharmaceutical (11)
Pharmacy benefit managers (4)
Phase 1 (9335)
Phase 2 (12481)
Phase 3 (10257)
Pipeline (2791)
Policy (66)
Postmarket research (906)
Preclinical (2896)
Press Release (67)
Prostate cancer (116)
Psychedelics (15)
Radiopharmaceuticals (147)
Rare diseases (355)
Real estate (2158)
Recruiting (13)
Regulatory (8231)
Reports (21)
Research institute (595)
Resumes & cover letters (192)
Rett syndrome (23)
RNA editing (3)
RSV (22)
Schizophrenia (82)
Series A (87)
Series B (79)
Sickle cell disease (43)
Special edition (12)
Spinal muscular atrophy (55)
Sponsored (12)
Startups (1282)
Stomach cancer (5)
Supply chain (29)
Tariffs (17)
The Weekly (39)
Vaccines (262)
Venture capital (37)
Weight loss (139)
Women's health (21)
Worklife (8)
Date
Today (2)
Last 7 days (237)
Last 30 days (933)
Last 365 days (13565)
2026 (1192)
2025 (13783)
2024 (15840)
2023 (17963)
2022 (23768)
2021 (25174)
2020 (23122)
2019 (17623)
2018 (13320)
2017 (13293)
2016 (11875)
2015 (15119)
2014 (11625)
2013 (9200)
2012 (9875)
2011 (10412)
2010 (9864)
Location
Africa (291)
Alabama (31)
Alaska (5)
Arizona (83)
Arkansas (5)
Asia (17030)
Australia (2796)
California (5212)
Canada (1477)
China (438)
Colorado (210)
Connecticut (239)
Delaware (152)
Europe (36561)
Florida (700)
Georgia (123)
Hawaii (3)
Idaho (29)
Illinois (318)
India (28)
Indiana (191)
Iowa (10)
Japan (276)
Kansas (48)
Kentucky (18)
Louisiana (11)
Maine (58)
Maryland (524)
Massachusetts (3781)
Michigan (119)
Minnesota (281)
Mississippi (2)
Missouri (55)
Montana (17)
Nebraska (15)
Nevada (55)
New Hampshire (34)
New Jersey (1472)
New Mexico (8)
New York (1191)
North Carolina (644)
North Dakota (4)
Northern California (2644)
Ohio (168)
Oklahoma (6)
Oregon (8)
Pennsylvania (933)
Puerto Rico (2)
Rhode Island (28)
South America (431)
South Carolina (20)
Southern California (1958)
Tennessee (82)
Texas (729)
United States (17731)
Utah (150)
Virginia (113)
Washington D.C. (25)
Washington State (403)
West Virginia (3)
Wisconsin (66)
Wyoming (2)
291,376 Results for "i3 corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies
January 6, 2026
·
2 min read
Press Releases
Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
December 23, 2025
·
5 min read
Press Releases
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
October 27, 2025
·
9 min read
Press Releases
SpyGlass Pharma Announces Positive 36-Month First-in-Human and 3-Month Phase I/II Trial Results for Its Novel BIM-IOL System
November 11, 2025
·
6 min read
Press Releases
IVOS Medical Joins NIH’s C3i Program to Accelerate Commercialization of BOSS G4™ Airway Management Technology
September 11, 2025
·
2 min read
Press Releases
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
October 27, 2025
·
1 min read
Policy
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
June 20, 2024
·
2 min read
Press Releases
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
October 20, 2025
·
9 min read
Press Releases
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
September 29, 2025
·
13 min read
Press Releases
Skye Provides 2026 Corporate Outlook
January 12, 2026
·
8 min read
1 of 29,138
Next
